白蛋白结合型紫杉醇单药治疗老年晚期非小细胞肺癌的临床观察被引量：8

Clinical observation of nab-paclitaxel monotherapy in elderly advanced nonsmall cell lung cancer

下载PDF

导出

摘要目的探讨白蛋白结合型紫杉醇单药治疗老年晚期非小细胞肺癌的耐受性和临床疗效。方法回顾性分析50例接受白蛋白结合型紫杉醇化疗的老年晚期非小细胞肺癌(NSCLC)患者的临床资料,化疗方案为白蛋白结合型紫杉醇260 mg/m^2,静脉滴注,第1天或分为第1天和第8天给药;21d为一个治疗周期,至少完成2个周期后评估疗效。结果 50例患者均可评估疗效,客观缓解率(ORR)为22%,疾病控制率(DCR)为78%,白蛋白紫杉醇的疗效与患者既往是否使用过紫杉类药物、病理类型及几线治疗等因素无关,差异无统计学意义(P﹥0.05)。中位无进展生存时间(PFS)为4个月,中位总生存时间(OS)为12个月。本研究主要不良反应为骨髓抑制、恶心呕吐、乏力、周围神经毒性及肝肾功能损害,且多为1~2级不良反应,药物耐受性良好。结论白蛋白结合型紫杉醇单药治疗老年晚期非小细胞肺癌疗效佳,耐受性良好。 Objective To investigate the clinical efficacy and adverse effects of nab-paclitaxel monotherapy in elder-ly advanced non-small cell lung cancer （NSCLC）. Method Clinical profile of 50 elderly patients with advanced NSCLC who received nab-paclitaxel monotherapy were retrospectively analyzed. All Patients were administered with intravenous injection of nab-paclitaxel at 260 mg/m2 on day l, or on day 1＋day 8, with 21 days as a cycle;The clinical efficacy was evaluated after two cycles at least. Result 50 patients were all evaluable. Overall, the objective response rate （ORR） was 22%, the disease control rates （DCR） was 78%. No correlation between the curative effect of nab-paclitaxel and the patho-logic types, prior use of paclitaxel-based medication and treatment lines were observed, while there was no statistically significant difference （P〉0.05）. Those patients had a median progression-free survival （PFS） of 4.0 months and a median overall survival （OS） of 12.0 months. For adverse reactions, myelosuppression, nausea, vomiting, fatigue, peripheral neu-rotoxicity and impaired hepatic/renal functions were commonly observed, and most of which were grade 1 or 2. Conclu-sion Nab-paclitaxel monotherapy is fairly effective and well tolerated in elderly patients with advanced non-small cell lung cancer.

作者魏雅萍李峻岭

机构地区北京协和医学院中国医学科学院肿瘤医院内科

出处《癌症进展》 2016年第4期353-356,共4页 Oncology Progress

关键词晚期非小细胞肺癌白蛋白结合型紫杉醇化疗 advanced non-small cell lung cancer nab-paclitaxel chemotherapy

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献13

1Ping Y, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at MayoClinic from 1997 to 2003[J]. Chest, 2005, 128(1): 452-462.
2Scagliotti GV, Parikh P, Pawel J von, et al. PhaseⅢ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced- stage non-small-cell lung cancer[J]. J Clin Oncol, 2008, 26 (21): 3543-3551.
3Reck M, Pawel J von, Zatloukal P, et al. Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevaci- zumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil[J]. J Clin Oncol, 2009, 27(8), 1227- 1234.
4Gradishar W J, Tjulandin S, Davidson N, et al. Phase Ⅲ tri- al of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer[J]. J Clin Oncol, 2005, 23(31): 7794-7803.
5Frasci G, Lorusso V, Panzan N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2000, 18(13): 2529-2536.
6Sun JM, Lee KW, Kim JH, et al. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer[J]. Jpn J Clin Oncol, 2009, 39(1): 27-32.
7Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus poly- sorbatebased docetaxel in multiple xenografts as a function of HER2 and SPARC status[J]. Anticancer Drugs, 2008, 19 (9): 899-909.
8Gradishar W J, Tjulandin S, Davidson N, et al. Phase Ⅲ tri-al ofnanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer[J]. J Clin Oncol, 2005, 23(31): 7794-7803.
9Socinski MA, Bondarenko l, Karaseva NA, et al. Weekly nabpaclitaxel in combination with carboplatin versus sol- vent-basedpaclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final re- sults of a phase Ⅲ trial[J]. J Clin Oncol, 2012, 30(17): 2055-2062.
10Shepherd FA, Dancey J, Ramlau R, et al. Prospective ran- domized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treat- ed with platinum-based chemotherapy[J]. J Clin Oncol, 2000, 18(10): 2095-2013.

二级参考文献13

1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J].CA Can- cerJ Clin, 2009, 59(4):225-249.
2Scagliotti GV, Parikh P, yon PawelJ, et al. Phase IIl study compar- ing cisplatin plus gemcitabine with cisplatin plus pemetrexed in che- motherapy-naive patients with advanced-stage non-small-cell lung cancer[]].J Clin Oncol, 2008, 26(21):3543-3551.
3Reck M, von PawelJ, Zatloukal P, et al. Phase llI trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil[J].J Cline Oncol, 2009, 27(8):1227-1234.
4Dienstmann R, Mardnez P, Felip E, et al. Personalizing therapy with targeted agents in non-small cell lung cancer[J].Oncotarget, 2011, 2(3):165-177.
5Vishnu P, Roy V. Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer[J].Breast Cancer (Auckl), 2011, 5:53-65.
6Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethyl- ated castor oil-based paclitaxel in women with breast cancer[J].J Clin Oncol, 2005, 23 (31):7794-7803.
7Eisenhauer EA, Therasse P, Bogaerts, et al. New response evalua- tion criteria in solid tumours:Revised recist guideline (version 1.1) [J]. EurJ Cancer, 2009, 45(2):228-247.
8Maria AB, Clorinda S, Antonio R. Treatment of advanced non- small cell lung cancer[J].J Thorac Dis, 2011, 3 (2):122-133.
9Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratu- mor paclitaxel concentrations, and endothelial cell transport of cre- mophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel[J]. Clin Cancer Res, 2006, 12(4): 1317-1324.
10BlumJL, Savin MA, Edelman G, et al. Phase lI study of weekly al- bumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes~. Clin Breast Cancer, 2007, 7(11): 850-856.